SCHEMBL1012937

SCHEMBL1012937

O=[N+]([O-])c1ccc2cccnc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ1A Q9NRL2 1/20 0.60
MAPT P10636 6/20 0.55
HTT P42858 4/20 0.55
TDP1 Q9NUW8 3/20 0.55
RAB9A P51151 3/20 0.55
NPC1 O15118 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
KDM4E B2RXH2 1/20 0.55
PKM P14618 1/20 0.55
NFKB1 P19838 1/20 0.55
CASP6 P55212 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
ALDH1A1 P00352 4/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30626616 1.00 BAZ1A (0.60) BAZ1AMAPTHTTTDP1RAB9A
Hydrochloric Acid SCHEMBL27777744 0.98 BAZ1A (0.59) BAZ1AMAPTHTTTDP1RAB9A
Formaldehyde SCHEMBL27533960 0.97 BAZ1A (0.58) BAZ1AMAPTHTTTDP1RAB9A
Quinoline SCHEMBL28125811 0.95 ALDH1A1 (0.57) BAZ1AMAPTHTTTDP1RAB9A
SCHEMBL366012 0.86 ALDH1A1 (0.62) BAZ1AMAPTHTTTDP1RAB9A
Quinoline SCHEMBL9110133 0.85 ALDH1A1 (0.66) BAZ1AMAPTHTTTDP1RAB9A
Hydrochloric Acid SCHEMBL27777765 0.84 ALDH1A1 (0.60) BAZ1AMAPTHTTTDP1RAB9A
SCHEMBL11012641 0.83 ALDH1A1 (0.51) BAZ1AMAPTHTTTDP1RAB9A
Dinitrophenylene SCHEMBL27728956 0.83 ALDH1A1 (0.58) BAZ1AMAPTHTTTDP1RAB9A
SCHEMBL9040936 0.81 KMT2A (0.61) BAZ1AMAPTRAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
CN-108727262-A A kind of synthetic method of the bromo- 7- methoxy quinolines of 3- 苏州康润医药有限公司 2018-11-02 CN claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
CN-102911116-A Metal-chelated azo compact disc dye preparation method SHANGHAI YONGHONG INDUSTRY GROUP CHEMICAL TECHNOLOGY CO LTD 2013-02-06 CN claimed
US-7732534-B2 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION (JP) 2010-06-08 US claimed
US-20080051519-A1 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION (JP) 2008-02-28 US claimed
US-20080051552-A1 Polymers functionalized with nitro compounds BRIDGESTONE CORPORATION 2008-02-28 US claimed
CN-122059875-A Method for synthesizing quinoline compound by catalytic dehydrogenation of tetrahydroquinoline compound 西安石油大学 2026-05-19 CN disclosed
CN-120757496-A Synthesis method of medicine intermediate 7-nitro-3- (trifluoromethyl) quinoline 福建凯昕药业有限公司 2025-10-10 CN disclosed
CN-120035438-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2025-05-23 CN disclosed
CN-119661432-A PRMT5 inhibitor, and pharmaceutical composition, pharmaceutical preparation and application thereof 北京福元医药股份有限公司 2025-03-21 CN disclosed
WO-2024132001-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2024-06-27 WO disclosed
CN-118059101-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2024-05-24 CN disclosed
EP-0858998-A1 Separation of 5-nitroquinoline and 8-nitroquinoline ELI LILLY AND COMPANY (US) 1998-08-19 EP disclosed
WO-1998033773-A1 SEPARATION OF 5-NITROQUINOLINE AND 8-NITROQUINOLINE ELI LILLY AND COMPANY (US) 1998-08-06 WO disclosed
US-5405843-A Anticancer drug potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1995-04-11 US disclosed
EP-0363212-B1 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS (JP) 1995-01-04 EP disclosed
US-5204348-A Quinoline derivatives MITSUI TOATSU CHEMICALS INC. (JP) 1993-04-20 US disclosed
US-5112817-A Anticancer Drug Potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-05-12 US disclosed
EP-0363212-A2 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR BAZ1A 4652/4885MAPT 150/4885HTT 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.